FDA Seeks Public Comment on Clinical Trial Design and Safety for Ibogaine Drug Products

What this means for your practice

This Request for Information (RFI) signals a significant, federally supported advancement in the regulatory pathway for novel psychedelic therapeutics. For healthcare businesses, particularly those specializing in addiction medicine, psychiatry, or contemplating future expansion into psychedelic-assisted therapies, this notice is crucial. While ibogaine is not yet an approved treatment, the FDA's proactive engagement in shaping clinical trial design, especially with HHS funding, indicates a serious effort to understand and regulate its development. This pre-market activity influences how these therapies might eventually be administered, monitored, and integrated into practice. Practitioners and clinic operators should monitor these developments closely, as successful clinical trials and subsequent approvals could lead to new treatment modalities that reshape scope of practice, facility requirements (due to 'care setting' and 'safety monitoring' considerations), and provider training in the long term. This RFI provides an opportunity for stakeholders to influence the regulatory framework from its early stages, ensuring future guidelines are practical and patient-centered.

Washington D.C. — The U.S. Food and Drug Administration (FDA) has announced a Request for Information (RFI) regarding the design and safety considerations for early-phase clinical trials involving ibogaine drug products. This notice, published in the Federal Register, describes the Agency's intent to gather public comments, data, and information to inform its approach to reviewing Investigational New Drug Applications (INDs) for ibogaine.

Context of Federal Funding and Regulatory Framework

This RFI comes as the Department of Health and Human Services (HHS) has committed to funding the clinical development of ibogaine. The initial federally supported trials are anticipated to investigate ibogaine's efficacy and safety in adults with opioid use disorder (OUD) and post-traumatic stress disorder (PTSD). This federal investment underscores a growing interest in novel therapeutic approaches for these challenging conditions.

The FDA's current effort builds upon its existing guidance for industry titled “Psychedelic Drugs: Considerations for Clinical Investigations.” By seeking specific input on ibogaine, the Agency aims to refine and tailor its regulatory oversight to the unique characteristics of this compound, particularly given the federal government's direct financial support for its research.

Key Areas of Focus for Public Comment

The FDA is particularly interested in receiving detailed feedback on several critical protocol elements pertinent to ibogaine development. These include:

• Dose Selection and Escalation: Strategies for determining safe and effective dosages and how doses should be increased over time in clinical settings.
• Care Setting: Considerations for the appropriate environment in which ibogaine should be administered, recognizing the potential need for specialized monitoring.
• Safety Monitoring: Protocols and methodologies for robustly monitoring patient safety during and after ibogaine administration.
• Eligibility Criteria: Guidelines for selecting appropriate study participants, including any contraindications or specific patient characteristics that should be considered.
• Stopping Rules: Criteria for discontinuing a trial or treatment arm if specific safety concerns or adverse events arise.
• Safety Oversight: Mechanisms for ensuring comprehensive oversight of patient safety throughout the trial duration.

The information gathered through this RFI will be instrumental in shaping the FDA's review process for INDs involving ibogaine, ensuring that future clinical investigations are designed to maximize patient safety and yield reliable data on efficacy.

Submitting Comments and Information

The FDA encourages all interested parties—including researchers, healthcare providers, patient advocacy groups, and the public—to submit comments, data, or information. Submissions must be made by November 20, 2026. Electronic submissions can be made via the Federal eRulemaking Portal at www.regulations.gov. Written/paper submissions can be mailed to the Dockets Management Staff at the FDA. All submissions must include Docket No. FDA-2026-N-10429 for “Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information.”

Confidential information must be submitted as a written/paper submission, with two copies: one containing the confidential information clearly marked, and a second redacted copy for public viewing.

Implications for Future Therapies

This RFI represents an early but significant step in the potential development of ibogaine as a therapeutic agent. By proactively engaging with stakeholders on clinical trial design and safety, the FDA is laying the groundwork for a rigorous and well-informed regulatory pathway. The involvement of HHS funding further underscores the national health priority placed on finding new treatments for conditions like OUD and PTSD. Healthcare professionals and organizations should closely observe these regulatory developments, as they may eventually lead to new treatment options and associated practice standards.

Key Facts

Frequently Asked Questions

What is the FDA requesting information about?

The FDA is requesting information on the design of early-phase clinical trials for ibogaine drug products, particularly concerning protocol elements like dose selection, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight.

Why is the FDA focusing on ibogaine?

The Department of Health and Human Services (HHS) is funding clinical development of ibogaine, with the first federally supported trials expected to study ibogaine for opioid use disorder and PTSD.

What existing guidance is this RFI building upon?

This RFI builds on the guidance for industry titled “Psychedelic Drugs: Considerations for Clinical Investigations.”

When is the deadline to submit comments?

Comments, data, or information must be submitted by November 20, 2026.

How will the FDA use the submitted information?

The FDA will consider all submitted information to inform whether and how specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.

Source: FDA — Notice: Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information · 2026-10-06